Joy Duemke: Optimizing Stem Cell Collection for Gene Therapy Success
Joy Duemke, Director of Marketing and Commercialization in North America at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“Gene therapy is creating new possibilities for patients with genetic hemoglobinopathies, but collecting sufficient, high-quality hematopoietic progenitor cells (HPCs) can be particularly challenging due to the impact of the underlying disease on mobilization.
Optimizing these procedures is an important step in helping more patients benefit from these therapies.
We appreciate AABB and presenting faculty, including Dr. John Manis, behind ‘Optimizing Apheresis Starting Material Collections for Stem Cell Gene Therapy Manufacturing for Patients with Genetic Hemoglobinopathies’ for tackling these challenges head-on to help ensure more SCD and thalassemia patients can benefit from these breakthrough therapies.
Register for the program on Wednesday, August 12, from 2:00–3:00 PM ET.”
Stay updated with Hemostasis Today.
-
Jul 21, 2026, 11:48A Century of VWD: Redefining Its Role Beyond Hemostasis
-
Jul 21, 2026, 07:55A New Era of Precision Imaging for Venous Thromboembolism – JTH
-
Jul 21, 2026, 07:43How to Monitor and Manage Unfractionated Heparin in Practice – JTH
-
Jul 21, 2026, 07:23Arthur Allen: Advancing Outpatient Antithrombotic Stewardship Through ADAPT
-
Jul 21, 2026, 03:19Where Does Stroke Treatment Go Next on The Latest ESOC 2026 TV Studio Session – ESO
-
Jul 21, 2026, 03:09Francesca Palandri: New Insights Into Anemia Management in Myelofibrosis
-
Jul 21, 2026, 01:57A New Approach to Understanding Plasmin Generation and Fibrinolysis – RPTH Journal
-
Jul 21, 2026, 01:52Maria Diaz Alonso: Delivering My First International Oral Presentation at ISTH 2026
-
Jul 21, 2026, 01:44Megan Preece: Presenting New Research on Antiphospholipid Syndrome at ISTH 2026